Glutathione research monograph — the tripeptide antioxidant and its clinical record

Glutathione is the most abundant intracellular antioxidant in mammalian biology
and one of the most-discussed compounds in research-vendor catalogues, where it
sits in a category of its own — neither a true peptide-research compound like
BPC-157 nor a peptide therapeutic like the GLP-1 agonists. It is a defined small
molecule with decades of published clinical literature, much of it directly in
humans. This monograph lays out what glutathione actually is, what its biology
does and does not explain, what the research record looks like (it is unusually
large), what community protocols report, and what to demand of a vendor before
evaluating any product.

Chemical identity and structure.
Glutathione (GSH) is a tripeptide composed of three amino acids — glutamate,
cysteine, and glycine — joined by an unusual gamma-peptide bond between the
glutamate side-chain carboxyl and the cysteine amine (rather than the usual
alpha-peptide bond seen in protein chemistry). The full sequence is
γ-L-glutamyl-L-cysteinyl-glycine; the molecular formula is C₁₀H₁₇N₃O₆S and the
molecular weight is 307.3 g/mol. The thiol (–SH) group on the cysteine residue
is the chemically active centre and is what makes glutathione a redox-cycling
molecule. The oxidised form, GSSG, is a disulfide-linked dimer of two GSH
molecules; the GSH:GSSG ratio inside a healthy cell is approximately 100:1,
and the ratio itself is a widely-used research marker of intracellular oxidative
state.

Mechanism of action.
Glutathione's research relevance derives from three biochemical roles. First,
it is the principal substrate for glutathione peroxidase, the enzyme that
detoxifies hydrogen peroxide and lipid peroxides — this is the antioxidant role
that most discussion focuses on. Second, it is a conjugation partner used by
glutathione S-transferases to render lipophilic xenobiotics water-soluble for
biliary or renal excretion — this is the Phase II detoxification role
extensively studied in toxicology. Third, it maintains the reduced state of
protein cysteines (the "redox buffer" function), which affects the activity of
hundreds of enzymes, transcription factors, and structural proteins. Unlike
many small molecules, glutathione is not a receptor agonist — its effects are
distributed across the metabolome rather than mediated through a single target.

Research applications and the evidence base.
Glutathione has, unusually for this corner of the market, a large body of
published human clinical research. Studies in oral, intravenous, intranasal,
nebulized, and topical glutathione have been published across hepatology
(non-alcoholic fatty liver, paracetamol toxicity), neurology (Parkinson's,
oxidative stress in neurodegeneration), pulmonology (cystic fibrosis,
chronic bronchitis), dermatology (skin-tone research and melanogenesis
modulation), and post-chemotherapy supportive-care contexts. PubMed and
EuropePMC together carry hundreds of glutathione clinical trials and
mechanistic papers. This makes glutathione one of the few compounds in
research-vendor catalogues with a genuinely substantial human evidence base —
even where individual study findings are mixed or modest, the literature exists
and can be read directly.

Community protocol information.
Glutathione is sold in vendor catalogues as raw lyophilized GSH, typically in
750 mg or 1500 mg vial sizes. Three administration routes dominate community
protocols: subcutaneous (most common in self-research contexts), intravenous
push (clinic settings only), and nebulized (for pulmonary research questions).
Reported research doses vary widely with route. Subcutaneous protocols
typically report 100–300 mg per administration, two to three times weekly,
in cycles of four to twelve weeks. Nebulized protocols report 150–600 mg per
session. The oral route is generally considered to have low bioavailability for
intact GSH because the tripeptide is largely hydrolysed in the gut, though
liposomal and acetylated formulations are reported to perform better. Because
glutathione has poor solution stability, vials are typically reconstituted
immediately before use and not stored for extended periods. None of these
numbers constitute a clinical recommendation — they are summaries of community
protocols and should be read alongside the route-dependent pharmacokinetics
literature.

Stack combinations researchers commonly use.
Glutathione is most frequently stacked with its direct biochemical precursors
and cofactors: N-acetylcysteine (NAC, the rate-limiting cysteine donor for
endogenous GSH synthesis), alpha-lipoic acid (which recycles oxidised GSSG back
to GSH), and vitamin C (which works in parallel as a hydrophilic antioxidant).
Researchers studying dermal questions sometimes combine glutathione with GHK-Cu
or vitamin C; researchers studying hepatology questions sometimes combine it
with silymarin or NAC. The pharmacology of these combinations is reasonably
well-characterized, unlike most stacks involving research-grade peptides.

Storage and handling.
Lyophilized glutathione is hygroscopic and oxidation-sensitive. Vials should be
kept refrigerated (2–8 °C), protected from light, and used soon after
reconstitution — most vendors recommend discarding reconstituted solution
within 7–14 days even when refrigerated, and many community protocols
reconstitute single-use only because the reduced thiol oxidises in solution
faster than peptide degradation drives most other compounds. Avoid all
freeze-thaw cycles. The lyophilized powder should appear white to off-white;
any yellowing of the powder or the solution indicates oxidation and should
prompt re-checking the COA and discarding the batch.

Quality and COA considerations.
A meaningful COA for glutathione should report identity (mass spectrometry
confirming the expected 307.3 g/mol molecular weight), purity (HPLC, ≥99% is a
reasonable benchmark for a defined small molecule), and — critically — the
reduced/oxidised ratio or a direct measure of the active thiol content. A
sample of GSH that has partially oxidised to GSSG during manufacturing or
storage will pass an HPLC purity test (GSSG is a "related substance," not an
impurity) but will deliver less of the active reduced form per milligram than
the label implies. Endotoxin testing should also be reported if the vial is
being used in any model that touches injection or tissue contact.

*Research-use note: This monograph is an educational summary of the published
research literature and community-reported protocols for glutathione (GSH).
Glutathione has more human clinical research behind it than most compounds in
research-vendor catalogues, but none of the route-and-dose protocols described
above is an approved therapy for the indications discussed, and intravenous
glutathione is administered in clinical settings only. Nothing here is medical
advice or a usage recommendation.*